Immunocore Holdings plc(NASDAQ:IMCR) 
Immunocore Holdings plc, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase 3 clinical trial in patients with previously untr...
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-11-07 | 2023-06-30 | 2023-05-10 | 2023-03-01 | 2022-12-31 | 2022-11-09 | 2022-08-09 | 2022-05-11 | 2021-12-31 | 2021-11-10 | 2021-08-11 | 2021-03-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenue: | |||||||||||||||||||||||
revenue from sale of therapies | 106,677,000 | 104,478,000 | 103,693,000 | 97,964,000 | 93,881,000 | ||||||||||||||||||
total revenue | 106,677,000 | 104,478,000 | 103,693,000 | 97,964,000 | 93,881,000 | 84,052,000 | 80,248,000 | 75,400,000 | 70,502,000 | 249,365,112 | 62,888 | 60,704 | 44,541 | 173,591 | 37,212 | 45,871 | 32,002 | 22,474 | 6,593 | 5,924 | 5,733 | 8,270 | |
yoy | 13.63% | 24.30% | 29.22% | 29.93% | 33.16% | -66.29% | 127504.63% | 124109.28% | 158185.62% | 143550.95% | 69.00% | 32.34% | 39.18% | 672.41% | 464.42% | 674.32% | 458.21% | 171.75% | |||||
qoq | 2.10% | 0.76% | 5.85% | 4.35% | 11.69% | 4.74% | 6.43% | 6.95% | -71.73% | 396422.57% | 3.60% | 36.29% | -74.34% | 366.49% | -18.88% | 43.34% | 42.40% | 240.88% | 11.29% | 3.33% | -30.68% | ||
cost and operating expenses: | |||||||||||||||||||||||
cost of revenue from sale of therapies | -434,000 | -2,703,000 | -513,000 | -1,040,000 | -831,000 | ||||||||||||||||||
research and development expense | -61,113,000 | -78,821,000 | -70,572,000 | -69,008,000 | -56,468,000 | -40,325,250 | -52,770,000 | -51,072,000 | -57,459,000 | ||||||||||||||
selling, general and administrative expense | -37,850,000 | -42,645,000 | -39,779,000 | -42,791,000 | -40,198,000 | -28,364,250 | -35,532,000 | -38,638,000 | -39,287,000 | ||||||||||||||
income from operations | 7,280,000 | -19,691,000 | -7,171,000 | -14,875,000 | -3,616,000 | -19,452,000 | -8,502,000 | -16,017,000 | -26,490,000 | ||||||||||||||
yoy | -301.33% | 1.23% | -15.66% | -7.13% | -86.35% | ||||||||||||||||||
qoq | -136.97% | 174.59% | -51.79% | 311.37% | -81.41% | 128.79% | -46.92% | -39.54% | |||||||||||||||
operating margin % | 6.82% | -18.85% | -6.92% | -15.18% | -3.85% | -23.14% | -10.59% | -21.24% | -37.57% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
other income: | |||||||||||||||||||||||
interest income | 3,418,000 | 3,906,000 | 4,123,000 | 4,271,000 | 4,176,000 | 5,173,000 | 5,960,000 | 6,239,000 | 8,246,000 | ||||||||||||||
interest expense | -3,051,000 | -3,053,000 | -3,043,000 | -3,045,000 | -3,025,000 | -7,038,000 | -4,290,000 | -4,277,000 | -3,239,000 | ||||||||||||||
foreign currency gains | 3,849,000 | ||||||||||||||||||||||
other income | 1,776,000 | 4,504,000 | 5,062,000 | 4,693,000 | 5,469,000 | 993,000 | 8,962,000 | 4,433,000 | |||||||||||||||
net income before income taxes | 13,272,000 | -826,500 | 304,000 | 6,084,000 | -7,029,000 | 6,093,000 | |||||||||||||||||
income tax expense | -301,000 | -606,000 | -1,061,000 | -1,486,000 | -357,000 | ||||||||||||||||||
net income | 12,971,000 | -30,060,000 | -177,000 | -10,300,000 | 5,023,000 | -23,771,000 | 8,736,000 | -11,616,000 | -24,436,000 | ||||||||||||||
yoy | 158.23% | 26.46% | -102.03% | -11.33% | -120.56% | ||||||||||||||||||
qoq | -143.15% | 16883.05% | -98.28% | -305.06% | -121.13% | -372.10% | -175.21% | -52.46% | |||||||||||||||
net income margin % | 12.16% | -28.77% | -0.17% | -10.51% | 5.35% | -28.28% | 10.89% | -15.41% | -34.66% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
other comprehensive income: | |||||||||||||||||||||||
exchange differences on translation of foreign operations | -7,289,000 | 1,922,000 | -3,392,000 | 6,476,000 | 673,000 | -2,590,000 | 3,247,000 | 944,000 | 897,000 | 380 | -323 | 205 | 18 | -38 | -38 | -92 | |||||||
total comprehensive income | 5,682,000 | -424,250 | -3,569,000 | -3,824,000 | 5,696,000 | -5,557,000 | 11,983,000 | ||||||||||||||||
basic net income per share | 0.26 | -0.028 | 0.1 | -0.138 | 0.17 | ||||||||||||||||||
basic weighted-average number of shares outstanding | 50,754,763 | 50,403,717 | 50,086,684 | 50,021,939 | |||||||||||||||||||
diluted net income per share | 0.25 | -0.028 | 0.1 | -0.138 | 0.17 | ||||||||||||||||||
diluted weighted-average number of shares outstanding | 52,934,787 | 50,403,717 | 51,949,798 | 52,808,434 | |||||||||||||||||||
collaboration revenue | 53,000 | 160,000 | 10,690,839 | 2,161 | 2,860 | 2,489 | 32,521 | 3,367 | 5,451 | 4,302 | 11,963 | ||||||||||||
foreign currency gain | -1,460,000 | 1,333,000 | -738,000 | 3,080,000 | -4,497,000 | 3,963,000 | |||||||||||||||||
income tax benefit | -14,266,000 | -481,000 | 1,050,000 | 2,643,000 | |||||||||||||||||||
net loss before income taxes | -9,694,000 | -10,130,000 | -24,079,000 | ||||||||||||||||||||
basic and diluted net loss per share | -0.2 | -0.23 | -0.49 | ||||||||||||||||||||
basic and diluted weighted-average number of shares outstanding | 50,345,666 | 50,294,205 | 49,991,064 | 50,014,086 | 49,877,218 | 48,888,975 | |||||||||||||||||
product revenue | 56,484,250 | 80,248,000 | 75,347,000 | 70,342,000 | 238,674,273 | 60,727 | 57,844 | 42,052 | 130,610 | 35,859 | 37,023 | 23,992 | 7,682 | ||||||||||
cost of product revenue | -600,250 | -448,000 | -1,707,000 | -246,000 | -1,036,731 | -269 | -1,126 | -178 | -548 | -70 | -70 | -34 | -248 | ||||||||||
foreign currency loss | -508,000 | -2,406,000 | |||||||||||||||||||||
total comprehensive loss | -10,672,000 | -23,539,000 | |||||||||||||||||||||
other expense | -190,000 | ||||||||||||||||||||||
pre-product, revenue | 3,397 | ||||||||||||||||||||||
research and development expenses | -9,673.25 | -38,693 | -36,560 | -17,266.5 | -25,943 | ||||||||||||||||||
selling and administrative expenses | -6,195 | -24,780 | -43,064 | -33,301 | -113,189 | -37,407 | -12,986 | -18,811 | -20,106 | ||||||||||||||
operating profit | -213.5 | -854 | |||||||||||||||||||||
finance income | 1,249.25 | 4,997 | 4,336 | 2,546 | 3,809 | 2,347 | 665 | 118 | 10 | 5 | 8 | 12 | 22 | ||||||||||
finance costs | -498.25 | -1,993 | -1,989 | -1,620 | -9,290 | -2,665 | -1,987 | -1,397 | -1,333 | -1,348 | -1,317 | -1,288 | -1,860 | ||||||||||
net finance income / | 751 | 3,004 | 2,347 | 926 | |||||||||||||||||||
profit before taxes | 537.5 | 2,150 | |||||||||||||||||||||
income tax credit | 5,602,824 | 176 | 3,528 | -2,702 | 1,385 | 2,151 | 1,655 | -214 | 2,125 | 2,813 | 4,681 | ||||||||||||
profit for the period | 581.5 | 2,326 | |||||||||||||||||||||
basic profit per share - / £ | 0.013 | 0.05 | |||||||||||||||||||||
diluted profit per share - / £ | 0.01 | 0.04 | |||||||||||||||||||||
basic weighted-average number of shares | 49,134,037 | ||||||||||||||||||||||
diluted weighted-average number of shares | 54,158,967 | ||||||||||||||||||||||
operating income | -10,338.75 | -41,355 | -20,046 | -17,387 | -47,833 | -20,367 | 6,872 | -6,993 | -16,460 | -37,832 | -30,950 | -34,499 | -31,881 | ||||||||||
loss before taxes | -8,741 | -34,964 | -53,314 | -5,865 | 5,550 | ||||||||||||||||||
income tax (charge) / credit | -74.25 | -297 | -192 | -236 | |||||||||||||||||||
loss for the period | -8,815.25 | -35,261 | -17,891 | -16,697 | -49,786 | -4,459.25 | 6,935 | -6,121 | -16,128 | -23,033.5 | -30,134 | -32,962 | -29,038 | ||||||||||
basic and diluted loss per share - / £ | -0.18 | -0.72 | -0.37 | ||||||||||||||||||||
weighted-average number of shares | 48,671,732 | ||||||||||||||||||||||
pre-product revenue | 10,460 | -2,014 | 3,708 | 2,829 | |||||||||||||||||||
total revenue from sale of therapies | 57,844 | 141,070 | 33,845 | 40,420 | 27,700 | ||||||||||||||||||
loss before taxation | -17,699 | ||||||||||||||||||||||
total revenue from sales of therapies | 42,052 | ||||||||||||||||||||||
research and development costs | -28,449 | -107,691 | -20,150 | -18,581 | -20,072 | -16,798 | -16,471 | -19,885 | |||||||||||||||
income before taxation | -16,461 | -8,272 | -17,783 | -25,438.25 | -32,259 | -35,775 | -33,719 | ||||||||||||||||
other comprehensive income | |||||||||||||||||||||||
other comprehensive income that is or may be reclassified to profit or loss in subsequent periods: | |||||||||||||||||||||||
total other comprehensive income for the period | 380 | ||||||||||||||||||||||
total comprehensive loss for the period | -16,317 | -6,444 | -15,923 | -23,056.5 | -30,172 | -33,000 | |||||||||||||||||
basic and diluted loss per share - £ | -0.35 | -0.14 | -0.37 | -0.91 | -0.69 | -0.75 | -0.76 | ||||||||||||||||
net other operating income | 4 | 2 | |||||||||||||||||||||
non-operating expense | -5,481 | -318 | -1,322 | -1,279 | -1,323 | -1,343 | -1,309 | -1,276 | |||||||||||||||
basic and diluted loss per share | -1.09 | ||||||||||||||||||||||
net other operating expense | |||||||||||||||||||||||
basic earnings per share - / £ | 0.14 | ||||||||||||||||||||||
diluted earnings per share - / £ | 0.13 | ||||||||||||||||||||||
net other operating income / | 1 | 40 | |||||||||||||||||||||
other comprehensive loss | |||||||||||||||||||||||
other comprehensive loss that is or may be reclassified to profit or loss in subsequent periods: | |||||||||||||||||||||||
total other comprehensive loss for the period | -323 | ||||||||||||||||||||||
other comprehensive income / | |||||||||||||||||||||||
other comprehensive income / (loss) that is or may be reclassified to profit or loss in subsequent periods: | |||||||||||||||||||||||
total other comprehensive income / (loss) for the period | 205 | ||||||||||||||||||||||
revenue | 6,593 | 5,924 | 5,733 | 8,270 | |||||||||||||||||||
net other operating (expense) / income | -17.5 | -28 | -82 | ||||||||||||||||||||
administrative expenses | -24,366 | -20,048 | -23,801 | -20,184 | |||||||||||||||||||
other comprehensive (loss) / income | |||||||||||||||||||||||
other comprehensive (loss) / income that is or may be reclassified to profit or loss in subsequent periods: | |||||||||||||||||||||||
total other comprehensive (loss) / income for the period | -23 | -38 | -38 | ||||||||||||||||||||
other comprehensive income that are or may be reclassified to profit or loss in subsequent periods: | |||||||||||||||||||||||
non-operating (expense) / income | -1,838 | ||||||||||||||||||||||
other comprehensive income that are or may be reclassified to profit or loss in subsequent periods | |||||||||||||||||||||||
total other comprehensive (loss) / income for the period, net of tax | -92 | ||||||||||||||||||||||
total comprehensive loss for the period, net of tax | -29,130 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-11-07 | 2023-09-30 | 2023-06-30 | 2023-05-10 | 2023-03-31 | 2022-12-31 | 2022-11-09 | 2022-09-30 | 2022-08-09 | 2022-06-30 | 2022-05-11 | 2022-03-31 | 2022-03-03 | 2022-03-01 | 2021-12-31 | 2021-11-10 | 2021-09-30 | 2021-08-11 | 2021-06-30 | 2021-03-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | |||||||||||||||||||||||||||||||
current assets | |||||||||||||||||||||||||||||||
cash and cash equivalents | 452,675,000 | 467,709,000 | 498,413,000 | 487,933,000 | 476,845,000 | 455,731,000 | 537,767,000 | 504,985,000 | 832,821,000 | 442,626,000 | 363,955 | 363,955 | 342,341 | 337,461 | 337,461 | 332,539 | 347,189 | 347,189 | 208,064 | 208,064 | 205,853 | 205,853 | 237,886,000 | 332,539 | 237,886 | 256,551 | 256,551 | 278,870 | 278,870 | 313,083 | 129,716 |
marketable securities | 392,221,000 | 396,444,000 | 393,940,000 | 394,878,000 | 360,185,000 | 364,645,000 | 363,515,000 | 354,612,000 | |||||||||||||||||||||||
accounts receivable | 81,068,000 | 73,977,000 | 75,880,000 | 69,761,000 | 63,094,000 | 63,009,000 | 63,659,000 | 60,245,000 | 57,754,000 | 52,093,000 | |||||||||||||||||||||
prepaid expenses and other current assets | 69,590,000 | 50,055,000 | 48,960,000 | 44,270,000 | 41,697,000 | 41,033,000 | 36,446,000 | 33,555,000 | 31,296,000 | 29,600,000 | |||||||||||||||||||||
inventory | 8,253,000 | 6,742,000 | 5,655,000 | 5,456,000 | 6,804,000 | 5,446,000 | 4,518,000 | 3,462,000 | 4,167,000 | 4,501,000 | 1,857 | 1,857 | 1,891 | 882 | 882 | 943 | 854 | 854 | 535 | 535 | 496 | 496 | 943 | ||||||||
total current assets | 1,003,807,000 | 996,742,000 | 1,022,848,000 | 1,002,298,000 | 948,625,000 | 929,864,000 | 1,005,905,000 | 956,859,000 | 926,038,000 | 528,820,000 | 415,692 | 415,692 | 395,055 | 385,908 | 385,908 | 391,881 | 403,521 | 403,521 | 257,103 | 257,103 | 243,384 | 243,384 | 262,726,000 | 391,881 | 262,726 | 289,871 | 289,871 | 311,496 | 311,496 | 339,519 | 152,931 |
property and equipment | 12,128,000 | 11,462,000 | 9,433,000 | 9,548,000 | 9,770,000 | 10,092,000 | 9,160,000 | 7,684,000 | 8,380,000 | 9,215,000 | |||||||||||||||||||||
operating lease right of use assets | 37,546,000 | 38,783,000 | 39,397,000 | 39,428,000 | 38,126,000 | 37,643,000 | 39,672,000 | 32,435,000 | 32,812,000 | 33,520,000 | |||||||||||||||||||||
other non-current assets | 18,614,000 | 20,282,000 | 16,489,000 | 17,036,000 | 17,132,000 | 17,117,000 | 17,238,000 | 16,276,000 | 15,996,000 | 14,473,000 | 8,846 | 8,846 | 7,895 | 7,033 | 7,033 | 7,342 | 6,749 | 6,749 | 6,243 | 6,243 | 5,955 | 5,955 | 7,342 | ||||||||
total assets | 1,072,095,000 | 1,067,269,000 | 1,102,500,000 | 1,082,387,000 | 1,028,008,000 | 1,009,506,000 | 1,084,638,000 | 1,023,365,000 | 993,987,000 | 597,001,000 | 464,119 | 464,119 | 440,360 | 430,534 | 430,534 | 435,518 | 444,673 | 444,673 | 295,568 | 295,568 | 282,037 | 282,037 | 301,773,000 | 435,518 | 301,773 | 330,740 | 330,740 | 353,013 | 353,013 | 381,147 | 197,194 |
liabilities and shareholders’ equity | |||||||||||||||||||||||||||||||
current liabilities | |||||||||||||||||||||||||||||||
accounts payable | 30,157,000 | 24,364,000 | 22,956,000 | 23,856,000 | 29,105,000 | 25,100,000 | 19,721,000 | 19,947,000 | 15,501,000 | 17,798,000 | |||||||||||||||||||||
accrued expenses and other current liabilities | 207,388,000 | 219,744,000 | 144,937,000 | 143,785,000 | 118,341,000 | 185,534,000 | 197,224,000 | 163,762,000 | 138,549,000 | 119,835,000 | |||||||||||||||||||||
deferred revenue, current | 572,000 | 583,000 | 582,000 | 594,000 | |||||||||||||||||||||||||||
operating lease liabilities, current | 1,996,000 | 2,006,000 | 1,878,000 | 1,843,000 | 1,717,000 | 1,547,000 | 1,097,000 | 1,387,000 | 1,243,000 | 1,388,000 | |||||||||||||||||||||
total current liabilities | 240,113,000 | 246,697,000 | 170,353,000 | 170,078,000 | 149,163,000 | 212,181,000 | 266,249,000 | 185,096,000 | 155,293,000 | 139,021,000 | 97,608 | 97,608 | 92,287 | 84,662 | 84,662 | 83,090 | 77,218 | 77,218 | 64,555 | 64,555 | 53,120 | 53,120 | 61,180,000 | 83,090 | 61,180 | 55,325 | 55,325 | 54,688 | 54,688 | 54,493 | 54,998 |
deferred revenue, non-current | 4,622,000 | 4,858,000 | 4,995,000 | 5,247,000 | 5,612,000 | 5,434,000 | 5,797,000 | 5,477,000 | 5,468,000 | 5,515,000 | |||||||||||||||||||||
operating lease liabilities, non-current | 40,027,000 | 41,556,000 | 41,397,000 | 42,561,000 | 40,748,000 | 40,162,000 | 41,271,000 | 33,445,000 | 33,986,000 | 34,633,000 | |||||||||||||||||||||
interest-bearing loans and borrowings | 393,660,000 | 393,125,000 | 392,587,000 | 392,060,000 | 391,530,000 | 391,013,000 | 438,121,000 | 437,544,000 | 48,011,000 | 38,484 | 38,484 | 37,116 | 38,677 | 38,677 | 39,500 | 45,563 | 45,563 | 41,536 | 41,536 | 38,370 | 38,370 | 37,226,000 | 39,500 | 37,226 | 37,280 | 37,280 | 36,135 | 36,135 | 36,437 | 36,654 | |
total liabilities | 678,422,000 | 686,236,000 | 705,936,000 | 693,906,000 | 649,529,000 | 648,790,000 | 706,811,000 | 664,228,000 | 634,453,000 | 228,158,000 | 172,576 | 172,576 | 163,086 | 156,441 | 156,441 | 156,762 | 149,854 | 149,854 | 130,916 | 130,916 | 118,739 | 118,739 | 130,226,000 | 156,762 | 130,226 | 128,853 | 128,853 | 130,874 | 130,874 | 135,350 | 141,848 |
commitments and contingencies | |||||||||||||||||||||||||||||||
shareholders’ equity | |||||||||||||||||||||||||||||||
ordinary shares (voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £149,633 and shares as of march 31, 2026 and december 31, 2025, respectively, and 50,831,928 and 50,689,271 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively. | 137,000 | ||||||||||||||||||||||||||||||
deferred shares, £0.0001 par value... | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | |||||||||||||||||||||
additional paid-in capital | 1,247,212,000 | 1,240,255,000 | 1,227,649,000 | 1,215,997,000 | 1,202,171,000 | 1,190,104,000 | 1,180,854,000 | 1,174,147,000 | 1,163,872,000 | 1,149,643,000 | |||||||||||||||||||||
accumulated deficit | -818,304,000 | -831,275,000 | -801,215,000 | -801,038,000 | -790,738,000 | -795,761,000 | -771,990,000 | -780,726,000 | -769,110,000 | -744,674,000 | -290,123 | -290,123 | -292,027 | -277,950 | -277,950 | -261,253 | -236,050 | -236,050 | -242,278 | -242,278 | -497,520 | -497,520 | -481,392,000 | -261,253 | -481,392 | -442,003 | -442,003 | -411,869 | -411,869 | -378,907 | -349,869 |
accumulated other comprehensive loss | -35,373,000 | -28,084,000 | -30,006,000 | -26,614,000 | -33,090,000 | -33,763,000 | -31,173,000 | -34,420,000 | -35,364,000 | -36,261,000 | |||||||||||||||||||||
total shareholders' equity | 393,673,000 | 396,564,000 | 388,481,000 | 378,479,000 | 377,827,000 | 359,137,000 | |||||||||||||||||||||||||
total liabilities and shareholders' equity | 1,072,095,000 | 1,102,500,000 | 1,082,387,000 | 1,028,008,000 | 1,084,638,000 | 1,023,365,000 | |||||||||||||||||||||||||
tax receivable | 1,815,000 | 2,365 | 2,365 | 11,688 | 14,510 | 14,510 | 13,231 | 13,231 | 11,289 | 11,289 | 9,632,000 | 11,688 | 9,632 | 22,555 | 22,555 | 20,428 | 20,428 | 17,615 | 12,935 | ||||||||||||
deferred tax assets | 14,333,000 | 14,077,000 | 14,355,000 | 14,790,000 | 12,663,000 | 10,111,000 | 10,761,000 | 10,973,000 | |||||||||||||||||||||||
ordinary shares (voting and non-voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £149,633 and £97,454 shares as of december 31, 2025 and 2024, respectively, and 50,689,271 and 50,064,860 shares issued and outstanding as of december 31, 2025 and 2024, respectively. | 136,000 | ||||||||||||||||||||||||||||||
total shareholders’ equity | 381,033,000 | 360,716,000 | 359,534,000 | 368,843,000 | |||||||||||||||||||||||||||
total liabilities and shareholders’ equity | 1,067,269,000 | 1,009,506,000 | 993,987,000 | 597,001,000 | |||||||||||||||||||||||||||
accrued expenses, non-current | 96,604,000 | 83,960,000 | 62,476,000 | 3,006,000 | 2,089,000 | 2,162,000 | 978,000 | ||||||||||||||||||||||||
ordinary shares (voting and non-voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £149,633 and £97,454 shares as of september 30, 2025 and december 31, 2024, respectively, and 50,467,954 and 50,064,860 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively. | 135,000 | ||||||||||||||||||||||||||||||
ordinary shares (voting and non-voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £149,633 and £97,454 shares as of june 30, 2025 and december 31, 2024, respectively, and 50,372,068 and 50,064,860 shares issued and outstanding as of june 30, 2025 and december 31, 2024, respectively. | 135,000 | ||||||||||||||||||||||||||||||
ordinary shares (voting and non-voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £97,234 and £97,454 shares as of march 31, 2025 and december 31, 2024, respectively, and 50,184,609 and 50,064,860 shares issued and outstanding as of march 31, 2025 and december 31, 2024, respectively. | 135,000 | ||||||||||||||||||||||||||||||
ordinary shares (voting and non-voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £97,454 and £109,355 shares as of december 31, 2024 and 2023, respectively, and 50,064,860 and 49,725,649 shares issued and outstanding as of december 31, 2024 and 2023, respectively. | 135,000 | ||||||||||||||||||||||||||||||
interest-bearing loans and borrowings, current | 48,207,000 | ||||||||||||||||||||||||||||||
interest-bearing loans and borrowings, non-current | 390,488,000 | ||||||||||||||||||||||||||||||
ordinary shares (voting and non-voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £97,454 and £109,355 shares as of september 30, 2024 and december 31, 2023, respectively, and 50,025,620 and 49,725,649 shares issued and outstanding as of september 30, 2024 and december 31, 2023, respectively. | 135,000 | ||||||||||||||||||||||||||||||
ordinary shares (voting and non-voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £97,454 and £109,355 shares as of june 30, 2024 and december 31, 2023, respectively, and 50,017,606 and 49,725,649 shares issued and outstanding as of june 30, 2024 and december 31, 2023, respectively. | 135,000 | ||||||||||||||||||||||||||||||
ordinary shares (voting and non-voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £97,454 and £109,335 shares as of march 31, 2024 and december 31, 2023, respectively, and 50,006,085 and 49,725,649 shares issued and outstanding as of march 31, 2024 and december 31, 2023, respectively. | 135,000 | ||||||||||||||||||||||||||||||
ordinary shares (voting and non-voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £109,335 shares as of december 31, 2023 and 2022, 49,725,649 and 48,088,346 shares issued and outstanding as of december 31, 2023 and 2022, respectively. | 134,000 | ||||||||||||||||||||||||||||||
non-current assets | |||||||||||||||||||||||||||||||
property, plant and equipment | 8,025 | 8,025 | 8,325 | 8,156 | 8,156 | 6,472 | 6,580 | 6,580 | 7,092 | 7,092 | 7,849 | 7,849 | 8,944,000 | 6,472 | 8,944 | 10,043 | 10,043 | 10,988 | 10,988 | 12,321 | 13,754 | ||||||||||
intangible assets | 1,589 | 1,589 | 410 | 410 | 410 | 410 | 410 | ||||||||||||||||||||||||
right of use assets | 25,832 | 25,832 | 24,233 | 24,742 | 24,742 | 25,173 | 23,963 | 23,963 | 21,853 | 21,853 | 22,199 | 22,199 | 22,593,000 | 25,173 | 22,593 | 22,772 | 22,772 | 22,391 | 22,391 | 22,742 | 23,093 | ||||||||||
deferred tax asset | 4,135 | 4,135 | 4,442 | 4,285 | 4,285 | 4,240 | 3,860 | 3,860 | 3,277 | 3,277 | 2,650 | 2,650 | 2,575,000 | 4,240 | 2,575 | 2,257 | 2,257 | 2,192 | 2,192 | 2,213 | 2,230 | ||||||||||
total non-current assets | 48,427 | 48,427 | 45,305 | 44,626 | 44,626 | 43,637 | 41,152 | 41,152 | 38,465 | 38,465 | 38,653 | 38,653 | 39,047,000 | 43,637 | 39,047 | 40,869 | 40,869 | 41,517 | 41,517 | 41,628 | 44,263 | ||||||||||
trade and other receivables | 49,880 | 49,880 | 48,458 | 45,200 | 45,200 | 46,711 | 40,968 | 40,968 | 35,273 | 35,273 | 25,746 | 25,746 | 15,208,000 | 46,711 | 15,208 | 10,765 | 10,765 | 12,198 | 12,198 | 8,821 | 10,280 | ||||||||||
equity | |||||||||||||||||||||||||||||||
share capital | 99 | 99 | 98 | 97 | 97 | 97 | 96 | 96 | 88 | 88 | 88 | 88 | 88,000 | 97 | 88 | 88 | 88 | 88 | 88 | 88 | 1 | ||||||||||
share premium | 146,205 | 146,205 | 137,957 | 128,744 | 128,744 | 123,751 | 120,147 | 120,147 | 579 | 579 | 212,499 | 212,499 | 212,238,000 | 123,751 | 212,238 | 211,930 | 211,930 | 211,286 | 211,286 | 211,286 | 386,230 | ||||||||||
foreign currency translation reserve | -4,266 | -4,266 | -1,663 | -2,717 | -2,717 | -3,097 | -1,759 | -1,759 | -29 | -29 | 294 | 294 | 89,000 | -3,097 | 89 | 71 | 71 | 33 | 33 | 71 | 163 | ||||||||||
other reserves | 337,847 | 337,847 | 337,847 | 337,847 | 337,847 | 337,847 | 337,847 | 337,847 | 337,847 | 337,847 | 386,167 | 386,167 | 386,167,000 | 337,847 | 386,167 | 386,167 | 386,167 | 386,167 | 386,167 | 386,167 | |||||||||||
share-based payment reserve | 101,781 | 101,781 | 95,062 | 88,072 | 88,072 | 81,411 | 74,538 | 74,538 | 68,445 | 68,445 | 61,770 | 61,770 | 54,357,000 | 81,411 | 54,357 | 45,634 | 45,634 | 36,434 | 36,434 | 27,092 | 18,821 | ||||||||||
total equity | 291,543 | 291,543 | 277,274 | 274,093 | 274,093 | 278,756 | 294,819 | 294,819 | 164,652 | 164,652 | 163,298 | 163,298 | 171,547,000 | 278,756 | 171,547 | 201,887 | 201,887 | 222,139 | 222,139 | 245,797 | 55,346 | ||||||||||
non-current liabilities | |||||||||||||||||||||||||||||||
non-current accruals | 2,531 | 2,531 | 1,646 | 824 | 824 | 1,479 | 1,479 | ||||||||||||||||||||||||
deferred revenue | 4,331 | 4,331 | 4,331 | 4,331 | 4,331 | 4,331 | 2,136 | 2,136 | 6,408,000 | 4,331 | 6,408 | 10,681 | 10,681 | ||||||||||||||||||
lease liabilities | 29,469 | 29,469 | 27,570 | 27,822 | 27,822 | 28,248 | 26,965 | 26,965 | 24,738 | 24,738 | 25,043 | 25,043 | 25,355,000 | 28,248 | 25,355 | 25,486 | 25,486 | 24,923 | 24,923 | 25,035 | 25,190 | ||||||||||
provisions | 153 | 153 | 136 | 125 | 125 | 114 | 108 | 108 | 87 | 87 | 70 | 70 | 57,000 | 114 | 57 | 81 | 81 | 175 | 175 | 160 | 138 | ||||||||||
total non-current liabilities | 74,968 | 74,968 | 70,799 | 71,779 | 71,779 | 73,672 | 72,636 | 72,636 | 66,361 | 66,361 | 65,619 | 65,619 | 69,046,000 | 73,672 | 69,046 | 73,528 | 73,528 | 76,186 | 76,186 | 80,857 | 86,850 | ||||||||||
trade and other payables | 93,135 | 93,135 | 85,754 | 78,158 | 78,158 | 75,076 | 64,928 | 64,928 | 48,133 | 48,133 | 34,695 | 34,695 | 35,436,000 | 75,076 | 35,436 | 28,815 | 28,815 | 27,027 | 27,027 | 26,359 | 25,728 | ||||||||||
corporation tax liability | 367 | 367 | 803 | ||||||||||||||||||||||||||||
total equity and liabilities | 464,119 | 464,119 | 440,360 | 430,534 | 430,534 | 435,518 | 444,673 | 444,673 | 295,568 | 295,568 | 282,037 | 282,037 | 301,773,000 | 435,518 | 301,773 | 330,740 | 330,740 | 353,013 | 353,013 | 381,147 | 197,194 | ||||||||||
tax credits receivable | 2,365 | ||||||||||||||||||||||||||||||
investment in sub-lease | 188 | 188 | 470 | 470 | 540 | 776 | |||||||||||||||||||||||||
other non-current financial assets | 4,935,000 | 4,935 | 5,609 | 5,609 | 5,476 | 5,476 | 3,812 | 4,410 | |||||||||||||||||||||||
deferred liabilities | 14,953 | 14,953 | 19,225 | 24,868 | |||||||||||||||||||||||||||
embedded derivative assets | |||||||||||||||||||||||||||||||
tax payable | |||||||||||||||||||||||||||||||
derivative liabilities |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-05-10 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-05-11 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities | |||||||||||||||||||||||
net income | 12,971,000 | 5,023,000 | |||||||||||||||||||||
adjustments for: | |||||||||||||||||||||||
share-based compensation expense | 6,302,000 | 8,339,000 | 9,837,000 | 10,033,000 | 9,489,000 | 8,667,000 | 6,559,000 | 10,000,000 | 8,964,000 | ||||||||||||||
depreciation | 948,000 | 834,000 | 798,000 | 780,000 | 854,000 | 1,166,000 | 1,035,000 | 992,000 | 1,011,000 | 4,086,031 | 1,368 | 1,316 | 1,285 | 1,285 | 1,337 | 1,477 | 1,638 | 1,679 | 1,679 | ||||
unrealized foreign exchange gains | -3,490,000 | ||||||||||||||||||||||
unrealized gains on marketable securities | -1,776,000 | -4,504,000 | -5,062,000 | -4,693,000 | -5,469,000 | -1,062,000 | -8,902,000 | ||||||||||||||||
non-cash lease expense | 627,000 | 667,000 | 567,000 | 568,000 | 546,000 | 560,000 | 488,000 | 432,000 | 432,000 | ||||||||||||||
other | 534,000 | 537,000 | 527,000 | 540,000 | 509,000 | 303,000 | 584,000 | 953,000 | -2,000 | 411,989 | 198 | -169 | -18 | -18 | 68 | 130 | -130 | -1 | -1 | ||||
changes in assets and liabilities: | |||||||||||||||||||||||
decrease in accounts receivable | -7,930,000 | 836,000 | |||||||||||||||||||||
increase in prepayments and other current assets | -18,772,000 | -28,000 | |||||||||||||||||||||
increase in accounts payable | 5,974,000 | 1,418,000 | -287,000 | -6,929,000 | 3,342,000 | 5,884,000 | -776,000 | ||||||||||||||||
decrease in accrued expenses | -8,303,000 | ||||||||||||||||||||||
decrease in deferred revenue | -146,000 | -144,000 | -146,000 | 0 | -1,602 | -1,602 | 58 | -4,272 | -4,272 | -11,633 | -11,633 | ||||||||||||
increase in operating lease liabilities | -864,000 | 756,000 | |||||||||||||||||||||
decrease in other operating assets | 150,000 | ||||||||||||||||||||||
net cash from operating activities | -13,775,000 | -32,655,000 | -4,456,000 | 25,964,000 | 435,000 | -13,951,000 | 21,127,000 | 23,472,000 | -4,587,000 | 2,928,481 | -2,391 | 8,792 | 6,032 | 8,094 | -9,184 | -30,833 | -30,833 | -16,332 | -21,203 | -32,596 | -25,979 | ||
capital expenditures | -1,781,000 | 0 | -748,000 | -414,000 | -298,000 | 0 | -828,000 | -331,000 | -5,421,224 | -768 | -2,470 | -918 | -394 | -337 | -138 | -138 | -278 | -374 | -136 | -220 | |||
free cash flows | -15,556,000 | -32,655,000 | -5,204,000 | 25,550,000 | 137,000 | -13,951,000 | 20,299,000 | 23,141,000 | -2,492,743 | -3,159 | 6,322 | 5,114 | 7,700 | -9,521 | -30,971 | -30,971 | -16,610 | -21,577 | -32,732 | -26,199 | |||
cash flows from investing activities | |||||||||||||||||||||||
proceeds from sale of marketable securities | 6,000,000 | 2,000,000 | 6,000,000 | 0 | 10,000,000 | ||||||||||||||||||
purchase of property and equipment | -1,781,000 | -748,000 | -414,000 | -298,000 | -828,000 | -331,000 | -430,000 | ||||||||||||||||
net cash from investing activities | 4,219,000 | -880,000 | 5,252,000 | -30,414,000 | 9,702,000 | -3,540,000 | -828,000 | -350,331,000 | -430,000 | ||||||||||||||
cash flows from financing activities | |||||||||||||||||||||||
proceeds from exercise of share options | 656,000 | 1,866,000 | 3,670,000 | 2,551,000 | 198,000 | 298,000 | 5,754,000 | ||||||||||||||||
net cash from financing activities | 656,000 | 4,284,000 | 1,866,000 | 3,670,000 | 2,551,000 | -51,511,000 | 198,000 | -818,000 | 396,012,000 | ||||||||||||||
increase in cash and cash equivalents | -8,900,000 | 13,678 | 7,673 | 10,883 | 125,812 | -32,298 | |||||||||||||||||
net foreign exchange difference on cash held | -6,134,000 | -1,453,000 | 7,818,000 | 11,868,000 | 8,426,000 | -13,034,000 | 12,285,000 | -159,000 | -800,000 | 8,293,818 | 7,936 | -2,793 | -5,961 | -5,961 | 12,142 | 265 | 265 | -8 | 100 | -24 | -52 | ||
cash and cash equivalents at beginning of period | 467,709,000 | 0 | 0 | 455,731,000 | 0 | 0 | 442,626,000 | ||||||||||||||||
cash and cash equivalents at end of period | 452,675,000 | 10,480,000 | 11,088,000 | 476,845,000 | 32,782,000 | -327,836,000 | 832,821,000 | ||||||||||||||||
supplemental disclosure of cash flow and noncash information | |||||||||||||||||||||||
cash paid for interest | -5,031,000 | -5,032,000 | |||||||||||||||||||||
cash paid for income taxes, net of refunds | -13,000 | -2,075,000 | |||||||||||||||||||||
net loss | -30,060,000 | -177,000 | -23,771,000 | 8,736,000 | -11,616,000 | -24,436,000 | |||||||||||||||||
unrealized foreign exchange losses | 2,300,000 | -2,907,000 | 100,000 | 1,304,000 | |||||||||||||||||||
loss on loan extinguishment | |||||||||||||||||||||||
deferred income taxes | |||||||||||||||||||||||
increase in accounts receivable | 1,994,000 | -5,989,000 | -1,295,000 | -2,192,000 | -2,663,000 | -6,198,000 | |||||||||||||||||
decrease in prepayments and other current assets | -5,690,000 | -1,852,000 | -2,239,000 | -1,819,000 | |||||||||||||||||||
increase in accrued expenses | -22,031,000 | 15,133,000 | 33,730,000 | -10,943,000 | -1,226,000 | 26,697,000 | 26,862,000 | 19,169,000 | |||||||||||||||
decrease in operating lease liabilities | -646,000 | -490,000 | |||||||||||||||||||||
increase in other operating assets | -4,706,000 | -1,573,000 | -3,533,000 | -1,395,000 | |||||||||||||||||||
decrease in other operating liabilities | |||||||||||||||||||||||
proceeds from sale of property, plant and equipment | 0 | 0 | 0 | 5 | 5 | 13 | 0 | ||||||||||||||||
purchase of marketable securities | 0 | 0 | 0 | 0 | |||||||||||||||||||
purchase of property, plant and equipment | -5,421,224 | -538 | -768 | -2,470 | -2,470 | -918 | -394 | -337 | -138 | -138 | -278 | -374 | -136 | -220 | |||||||||
proceeds from issue of ordinary shares | |||||||||||||||||||||||
exercise of share options | 34,323,544 | 8,249 | 9,214 | 4,993 | 4,993 | 3,605 | 3,152 | 1,123 | 261 | 261 | |||||||||||||
loan repayments | |||||||||||||||||||||||
debt prepayments and extinguishments | |||||||||||||||||||||||
non-current interest-bearing loan received | |||||||||||||||||||||||
debt issuance payments | |||||||||||||||||||||||
increase in net cash and cash equivalents | -780,000 | 12,688,000 | -69,002,000 | 20,497,000 | -327,677,000 | 390,995,000 | 183,419 | ||||||||||||||||
cash and cash equivalents at beginning of year | |||||||||||||||||||||||
cash and cash equivalents at end of year | |||||||||||||||||||||||
supplemental cash flow information | |||||||||||||||||||||||
cash received for interest | -5,031,000 | -16,520,000 | -4,832,000 | 6,976,000 | 5,141,000 | ||||||||||||||||||
cash paid for income taxes | -32,000 | -158,000 | -293,000 | 81,000 | -140,000 | ||||||||||||||||||
increase in other operating liabilities | 816,000 | -61,000 | 1,193,000 | ||||||||||||||||||||
proceeds from issue of convertible senior notes | 0 | ||||||||||||||||||||||
payments for debt issuance costs | 0 | -1,116,000 | -12,242,000 | ||||||||||||||||||||
purchases of property and equipment in accounts payable | |||||||||||||||||||||||
proceeds from issue of convertible loan notes | 402,500,000 | ||||||||||||||||||||||
supplemental disclosure of cash flow information | |||||||||||||||||||||||
supplemental disclosure of cash flow and non-cash information | |||||||||||||||||||||||
debt issuance costs in accrued expenses and other current liabilities | -1,116,000 | ||||||||||||||||||||||
purchases of property and equipment in accrued expenses and other current liabilities | |||||||||||||||||||||||
decrease in accounts payable | -2,320,000 | ||||||||||||||||||||||
cash received for income taxes | |||||||||||||||||||||||
loss for the period | 1,904 | -14,077 | -16,697 | -16,697 | 6,228 | -6,121 | -16,128 | -16,128 | -30,134 | -32,962 | -29,038 | ||||||||||||
equity settled share-based payment expense | 6,719 | 6,990 | 6,661 | 6,661 | 6,093 | 6,675 | 7,413 | 7,413 | |||||||||||||||
net finance (income) / costs | -2,459 | -1,847 | -926 | -926 | |||||||||||||||||||
foreign exchange movements | -9,656 | 3,381 | 5,725 | 5,725 | |||||||||||||||||||
income tax charge / | -144 | 151 | 236 | 236 | |||||||||||||||||||
working capital adjustments: | |||||||||||||||||||||||
increase in trade and other receivables and other non-current assets | -1,332 | ||||||||||||||||||||||
increase in trade and other payables | 6,540 | 10,066 | 2,111 | 11,246 | 16,027 | 12,281 | -807 | 6,384 | 631 | ||||||||||||||
decrease in current and non-current deferred revenue | -1,602 | ||||||||||||||||||||||
other working capital movements | 923 | -186 | -562 | -562 | 1,384 | -159 | -168 | -480 | -480 | ||||||||||||||
cash from operations | 2,459 | -2,391 | -935 | -935 | 6,036 | -28,716 | -21,203 | ||||||||||||||||
r&d tax credits received | 2,662 | ||||||||||||||||||||||
taxation paid | -3 | 0 | -177 | -177 | |||||||||||||||||||
purchase of intangible assets | |||||||||||||||||||||||
interest income receipts | 3,857 | ||||||||||||||||||||||
net cash flows from investing activities | 2,706 | -394 | 332 | 25 | |||||||||||||||||||
gross proceeds from issue of share capital | 0 | 0 | 0 | 0 | 226,528 | ||||||||||||||||||
costs from issue of share capital | 0 | 0 | 0 | 0 | -15,543 | ||||||||||||||||||
interest paid | -1,518 | -1,458 | -2,101 | -2,101 | |||||||||||||||||||
repayment of lease liabilities | -312 | -398 | -407 | -407 | -943 | -816 | -694 | -755 | -755 | -694 | -864 | -799 | -802 | ||||||||||
net cash flows from financing activities | 6,419 | 7,358 | 2,485 | -1,191 | 117,515 | -1,070 | -1,612 | 209,373 | |||||||||||||||
cash and cash equivalents at beginning of the period | 0 | 0 | 332,539 | 332,539 | 0 | 129,716 | |||||||||||||||||
cash and cash equivalents at end of the period | 21,614 | 4,880 | 337,461 | 337,461 | 139,125 | 2,211 | 205,853 | 205,853 | -22,319 | -34,213 | 313,083 | ||||||||||||
net cash from / (used in) operating activities | 8,792 | ||||||||||||||||||||||
net cash flows from / (used in) investing activities | |||||||||||||||||||||||
decrease in receivables and other non-current assets | 2,852 | -11,489 | |||||||||||||||||||||
taxation received | 9,904 | 9,904 | |||||||||||||||||||||
interest received | 2,076 | 2,076 | |||||||||||||||||||||
decrease / (increase) in receivables and other non-current assets | 2,852 | ||||||||||||||||||||||
increase / (decrease) in trade and other payables | 2,111 | ||||||||||||||||||||||
net cash flows used in investing activities | -394 | ||||||||||||||||||||||
net cash flows from / (used in) financing activities | 2,485 | ||||||||||||||||||||||
increase / (decrease) in cash and cash equivalents | 10,883 | ||||||||||||||||||||||
loss for the year | |||||||||||||||||||||||
equity settled share-based payment expenses | 8,723 | 9,200 | 9,342 | 8,596 | |||||||||||||||||||
net finance costs | 748 | 1,188 | 1,279 | 1,323 | 1,323 | 1,343 | 1,309 | ||||||||||||||||
income tax credit | 2,129 | -1,244 | -2,151 | -1,655 | -1,655 | 214 | -2,125 | -2,813 | -4,681 | ||||||||||||||
increase in receivables and other non-current assets | -7,069 | -5,070 | |||||||||||||||||||||
net taxation received | |||||||||||||||||||||||
proceeds from investment in sub-leases | 0 | 228 | 76 | 245 | |||||||||||||||||||
other investing activities | 1,660 | 597 | |||||||||||||||||||||
repayment of principal loan liability | |||||||||||||||||||||||
early settlement and other loan fees | |||||||||||||||||||||||
interest paid on non-current interest-bearing loans | |||||||||||||||||||||||
cash and cash equivalents at beginning of the year | 0 | 0 | 0 | 237,886 | 237,886 | 0 | |||||||||||||||||
cash and cash equivalents at end of the year | |||||||||||||||||||||||
foreign exchange differences | -11,690 | -9,753 | 945 | 945 | |||||||||||||||||||
net taxation paid | |||||||||||||||||||||||
interest paid on non-current interest-bearing loan | -1,245 | -967 | -838 | -838 | -1,674 | -850 | -813 | -810 | |||||||||||||||
net foreign exchange difference on cash | |||||||||||||||||||||||
cash flows used in investing activities | |||||||||||||||||||||||
(decrease) / increase in cash and cash equivalents | -32,298 | ||||||||||||||||||||||
net cash flows (used in) / generated by investing activities | -133 | -133 | |||||||||||||||||||||
net cash flows (used in) / generated by financing activities | -1,332 | -1,332 | |||||||||||||||||||||
(increase) / decrease in receivables and other non-current assets | -11,489 | ||||||||||||||||||||||
(decrease) / increase in trade and other payables | -807 | ||||||||||||||||||||||
depreciation of property, plant and equipment | 1,317 | 1,336 | 1,398 | 1,460 | |||||||||||||||||||
depreciation of right of use assets | 401 | 377 | 376 | 347 | |||||||||||||||||||
remeasurement of leases | |||||||||||||||||||||||
amortization of intangible assets | |||||||||||||||||||||||
write-off of intangible assets | |||||||||||||||||||||||
loss on disposal of property, plant and equipment | -2 | -9 | 191 | ||||||||||||||||||||
profit on derecognition of leases | |||||||||||||||||||||||
unrealized foreign exchange differences | |||||||||||||||||||||||
decrease in trade and other receivables | 2,068 | ||||||||||||||||||||||
movement in provisions and other charges | -129 | -64 | 15 | 28 | |||||||||||||||||||
decrease in deferred liabilities | -4,275 | -5,215 | |||||||||||||||||||||
bank interest received on cash and cash equivalents | 0 | 0 | |||||||||||||||||||||
leasehold incentive | |||||||||||||||||||||||
net cash flows (used in) from investing activities | |||||||||||||||||||||||
cash flows from financing activities - sum | |||||||||||||||||||||||
remeasurement of right of use assets | |||||||||||||||||||||||
foreign exchange loss | 936 | ||||||||||||||||||||||
increase in trade and other receivables | 1,300 | ||||||||||||||||||||||
net income tax credit received | |||||||||||||||||||||||
lease capital contribution | |||||||||||||||||||||||
loss / (gain) on disposal of property, plant and equipment | |||||||||||||||||||||||
increase/(decrease) in cash and cash equivalents | |||||||||||||||||||||||
foreign exchange (gain) / loss | |||||||||||||||||||||||
net finance costs/ | 1,838 | ||||||||||||||||||||||
foreign exchange translation differences | -368 | ||||||||||||||||||||||
increase in deferred liabilities | -7,051 | ||||||||||||||||||||||
gross gain from sale of equity investment | |||||||||||||||||||||||
taxation charge | |||||||||||||||||||||||
gross proceeds from disposal of equity investment | |||||||||||||||||||||||
proceeds from sub-leases | |||||||||||||||||||||||
net cash flows from / (used) in investing activities |